Ultrasound-Assisted Liposomes: A Scalable Platform For GLP-1 Peptide Delivery

Nov 20, 2026

Leave a message

From semaglutide to next-generation lipidated peptides - why sonication is the key to oral and commercial-scale manufacturing.

GLP-1 peptides such as semaglutide are structurally unstable, prone to degradation, and remain mostly injectable. Even approved oral semaglutide shows bioavailability below 1%, driving higher doses, cost and formulation complexity. Liposomal encapsulation is a mature, membrane-mimicking carrier that can protect sensitive APIs and improve absorption - but its performance is governed less by lipid choice than by the preparation process. That is where ultrasound enters.

From semaglutide to next-generation lipidated peptides - why sonication is the key to oral and commercial-scale manufacturing. GLP-1 peptides such as semaglutide are structurally unstable, prone to degradation, and remain mostly injectable. Even approved oral semaglutide shows bioavailability below 1%, driving higher doses, cost and formulation complexity. Liposomal encapsulation is a mature, membrane-mimicking carrier that can protect sensitive APIs and improve absorption - but its performance is governed less by lipid choice than by the preparation process. That is where ultrasound enters.  Figure 1. Liposome suspension prepared by ultrasonic dispersion (water / lecithin). Why Sonication High-intensity ultrasound induces acoustic cavitation, generating local shear and micro-mixing that break up lipid aggregates and shrink multilamellar vesicles into small, uniform liposomes. Semaglutide and tirzepatide already carry lipid tails that insert naturally into the phospholipid bilayer, so they load efficiently without complex conjugation. Encapsulation efficiency, particle size and dispersion stability are all tuned by sonication - in a controlled, repeatable way. 视频:https://youtu.be/h1Q_ANLFOjg?si=_nC_kewMiEGW5cBj Scalable by Design Unlike batch nanoparticle methods that depend on reactor geometry, sonication scales by energy density, so lab recipes transfer cleanly to pilot and production. For commercial manufacturing, continuous-flow sonication is the most practical format: the dispersion passes through a fixed-volume chamber under controlled pressure, amplitude, temperature and residence time - critical for heat-sensitive peptide liposomes.  Figure 2. Industrial ultrasonic continuous-flow cell. From Lab Line to Production Line A complete ultrasonic platform covers the whole workflow: the YPS17B-HB lab-scale sonochemical unit for formulation screening and small-batch trials, and the circulating industrial YPS61B-MB for continuous, high power-density, GMP-aligned production with linear scale-up.  Figure 3. Scale-up path: Initial Lab Trials → Process Optimization → Production-Scale Solution. Beyond Semaglutide As GLP-1 therapy moves toward dual- and multi-agonist peptides and patient demand for oral delivery grows, a scalable encapsulation platform becomes strategically important. The same process logic applies to other lipidated peptides, peptide conjugates and novel biologics - turning lab discoveries into robust, commercial-scale products.
Figure 1. Liposome suspension prepared by ultrasonic dispersion (water / lecithin).

 

 

Why Sonication

High-intensity ultrasound induces acoustic cavitation, generating local shear and micro-mixing that break up lipid aggregates and shrink multilamellar vesicles into small, uniform liposomes. Semaglutide and tirzepatide already carry lipid tails that insert naturally into the phospholipid bilayer, so they load efficiently without complex conjugation. Encapsulation efficiency, particle size and dispersion stability are all tuned by sonication - in a controlled, repeatable way.

 

Scalable by Design

Unlike batch nanoparticle methods that depend on reactor geometry, sonication scales by energy density, so lab recipes transfer cleanly to pilot and production. For commercial manufacturing, continuous-flow sonication is the most practical format: the dispersion passes through a fixed-volume chamber under controlled pressure, amplitude, temperature and residence time - critical for heat-sensitive peptide liposomes.

news-908-674
Figure 2. Industrial ultrasonic continuous-flow cell.

 

From Lab Line to Production Line

A complete ultrasonic platform covers the whole workflow: the YPS17B-HB lab-scale sonochemical unit for formulation screening and small-batch trials, and the circulating industrial YPS61B-MB for continuous, high power-density, GMP-aligned production with linear scale-up.

2
Figure 3. Scale-up path: Initial Lab Trials → Process Optimization → Production-Scale Solution.

 

Beyond Semaglutide

As GLP-1 therapy moves toward dual- and multi-agonist peptides and patient demand for oral delivery grows, a scalable encapsulation platform becomes strategically important. The same process logic applies to other lipidated peptides, peptide conjugates and novel biologics - turning lab discoveries into robust, commercial-scale products.

Send Inquiry
Send Inquiry
Established in 1995, FYCG is a manufacturer of high-power ultrasonic equipment headquartered in Hangzhou. We specialise in the research, development and production of core components for high-power ultrasonic systems, and provide application solutions for high-power ultrasonic technology. We operate our own manufacturing lines, handling processing, assembly and sales in-house to ensure product quality. The company is ISO 9001 certified, and our products hold CE certification.